Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Decreases By 28.2%

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 35,200 shares, a decrease of 28.2% from the March 31st total of 49,000 shares. Currently, 1.9% of the company’s shares are sold short. Based on an average trading volume of 339,800 shares, the days-to-cover ratio is presently 0.1 days.

Tenax Therapeutics Trading Down 3.3 %

NASDAQ:TENX traded down $0.12 during mid-day trading on Friday, hitting $3.48. The company had a trading volume of 16,887 shares, compared to its average volume of 31,019. Tenax Therapeutics has a fifty-two week low of $3.47 and a fifty-two week high of $61.20. The business’s fifty day moving average is $3.95 and its two-hundred day moving average is $14.11.

Analyst Ratings Changes

Several research firms have weighed in on TENX. StockNews.com began coverage on Tenax Therapeutics in a research note on Wednesday, January 10th. They issued a “sell” rating on the stock. Roth Mkm reissued a “buy” rating on shares of Tenax Therapeutics in a research note on Tuesday, February 20th.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.